Used in research and therapeutic development targeting type I interferon signaling pathways. Blocks the interferon-alpha/beta receptor 1 (IFNAR1), modulating immune responses associated with autoimmune diseases such as systemic lupus erythematosus (SLE). Employed as a reference standard in antibody development and validation due to its well-characterized binding and neutralizing properties. Supports studies evaluating the role of interferon signaling in viral infections, inflammation, and cancer immunotherapy. Also utilized in preclinical models to assess efficacy and mechanism of action of anti-IFNAR1 therapies.